Virbac SA VIRP

H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT margin2 of 18.8% at CERS: Revenue growth is coming from both segments : companion animal +10.0% and farm animal +6.7% with a strong contribution from our Supercharge platforms (excl. Thyronorm) which increased by around +12% at CERS Solid volume/mix effect of ~+5.4%, completed by price increase of ~+2%Operating margin increased by 0.5ppt compared to H1 2025 driven by a favorable mix effect on the gross margin partially offse

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsAugust, 31 20268 390 660Gross total of voting rights : 12 705 411Net total* of

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsJuly, 31 20268 390 660Gross total of voting rights : 12 705 412Net total* of v

First half 2026 revenue reached €768m : +7.4% at constant exchange rate and scope (CERS) vs H1 2025+4.0% at actual rates impacted by currency headwinds Balanced growth in both segments : companion animal +10.0% and farm animal +6.7% with a strong contribution from our Supercharge platforms (excl. Thyronorm) which increased by around +12% at CERS.Solid volume/mix effect of ~+5.4%, completed by price increase of ~+2%Strong first-half performance driven by double-digit growth in North America despi

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsJune, 30 20268 390 660Gross total of voting rights : 12 706 458Net total* of v

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsMay, 31 20268 390 660Gross total of voting rights : 12 706 758Net total* of vo

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsApril, 30 20268 390 660Gross total of voting rights : 12 707 056Net total* of

The North American Veterinary Community (NAVC) and the Human Animal Bond Research Institute (HABRI) today announced that Virbac Corporation (Virbac) has become Human-Animal Bond Certified, making a major commitment to training and education and expanding its partnership with HABRI, announced earlier this year. The Human-Animal Bond Certification, created by HABRI and the NAVC, provides a deeper understanding of the health benefits of pet ownership and human-animal interaction and how this inform

First-quarter 2026 revenue reached €384m : +7.7% at constant exchange rate and scope (CERS) vs Q1 2025+2.2% at actual rates impacted by significant currency headwinds Balanced growth in both segments : companion animal +9.9% and farm animal +8.4% with a strong contribution from our Supercharge platforms (excl. Thyronorm) with an increase of around +15% at CERS.Solid volume/mix effect of ~+6%, completed by price increase of ~+2%Excellent Q1 2026 performance driven by exceptional growth in North A

Full-year 2025 revenue reached €1,465m : +7.9% at constant exchange rate and scope (CERS) vs 2024+4.8% at actual rates impacted by significant currency headwinds, particularly in Latin America, IMEA and the Pacific. Strong companion animal growth of +10.9% and farm animal of +6.1% at CERS Solid volume/mix effect of ~+5%, completed by price increase of ~+3%Excellent performance in 2025 in the USA (+14.7% at CERS), followed by IMEA (+9.5%), Latin America (+7.5%) and Europe (+7.5%). Sustained growt